Zobrazeno 1 - 10
of 305
pro vyhledávání: '"YUKIO HOSOMI"'
Autor:
Tsuyoshi Hirata, MD, Yuji Uehara, MD, Taiki Hakozaki, MD, Takayuki Kobayashi, MD, Yuto Terashima, MD, Kageaki Watanabe, MD, Makiko Yomota, MD, PhD, Yukio Hosomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 6, Iss 1, Pp 100761- (2025)
Externí odkaz:
https://doaj.org/article/61fbb0694c7c4c1b84ab6693720282c6
Autor:
Kageaki Watanabe, MD, Yukio Hosomi, MD, PhD, Katsuhiko Naoki, MD, PhD, Yoshiro Nakahara, MD, PhD, Yoko Tsukita, MD, PhD, Hirotaka Matsumoto, MD, PhD, Kiyotaka Yoh, MD, Yasuhito Fujisaka, MD, PhD, Satoshi Takahashi, MD, PhD, Saori Takata, MD, PhD, Kazuhiro Usui, MD, PhD, Kazuma Kishi, MD, PhD, Go Naka, MD, PhD, Shu Tamano, MSS, Kohei Uemura, PhD, Hideo Kunitoh, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100720- (2024)
Introduction: Osimertinib is used as the first-line treatment for EGFR mutation-positive NSCLC. Nevertheless, its efficacy and safety in clinical practice remain to be fully elucidated and the pattern of progression and the optimal subsequent treatme
Externí odkaz:
https://doaj.org/article/55bb019de54c4270ba80a584e19e9d79
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Tsuyoshi Hirata, MD, Yuji Uehara, MD, Taiki Hakozaki, MD, Takayuki Kobayashi, MD, Yuto Terashima, MD, Kageaki Watanabe, MD, Makiko Yomota, MD, PhD, Yukio Hosomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100659- (2024)
Introduction: Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcom
Externí odkaz:
https://doaj.org/article/f8d1f14e741e43bb923d8e88043d79bf
Autor:
Tadatsugu Yoshinaga, Makiko Yomota, Kazutoshi Toriyama, Hirokazu Iso, Kie Mirokuji, Shoko Kawai, Kosuke Narita, Mikito Suzuki, Hirotoshi Horio, Yukio Hosomi
Publikováno v:
Respirology Case Reports, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract The features of intralobar pulmonary sequestration vary on computed tomography (CT). Many cases demonstrate a mass or cystic lesion within a lower lobe. We report herein a case of a 55‐year‐old, female patient presenting with right back
Externí odkaz:
https://doaj.org/article/4065e5f9e7254769ba8524a1340cd838
Autor:
Makiko Yomota, Masaru Tanaka, Takayuki Kobayashi, Masatake Kitano, Saori Ikeda, Yusuke Kanemasa, Noriyo Yanagawa, Yukio Hosomi
Publikováno v:
Respirology Case Reports, Vol 12, Iss 2, Pp n/a-n/a (2024)
Abstract We herein report a case of interstitial lung changes in a patient with prolonged coronavirus disease 2019 (COVID‐19) with follicular lymphoma receiving rituximab and bendamustine who recovered after treatment with a combination therapy con
Externí odkaz:
https://doaj.org/article/bcb99e819f1c4930b49015da37fd784b
Publikováno v:
Respirology Case Reports, Vol 11, Iss 11, Pp n/a-n/a (2023)
Key message In malignant pleural mesothelioma patients, pleural effusion may improve during the course of the disease. Pleural effusion with nodular shadows bordering the pleura should be followed up even if the pleural effusion improves.
Externí odkaz:
https://doaj.org/article/0d4a174e205a44e2a767e5ce2a381408
Publikováno v:
Thoracic Cancer, Vol 13, Iss 23, Pp 3408-3411 (2022)
Abstract Advanced thymic carcinomas have limited treatment options. Recently, lenvatinib was approved for advanced thymic carcinoma treatment. However, the clinical benefit of lenvatinib re‐administration in patients with advanced thymic carcinoma
Externí odkaz:
https://doaj.org/article/2c1f348c98ca40058bd1080baa3627ff
Autor:
Hideki Ikeda, MD, Joji Nagasaki, MD, PhD, Daiki Shimizu, MD, Yuki Katsuya, MD, PhD, Hidehito Horinouchi, MD, PhD, Yukio Hosomi, MD, PhD, Etsuko Tanji, MS, Takekazu Iwata, MD, PhD, Makiko Itami, MD, PhD, Masahito Kawazu, MD, PhD, Yuichiro Ohe, MD, PhD, Takuji Suzuki, MD, PhD, Yosuke Togashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100573- (2023)
Introduction: Unresectable or recurrent thymic epithelial tumors (TETs) have a poor prognosis, and treatment options are limited. This study aimed to investigate the immunologic significance of CD80/CD86 or major histocompatibility complex class II (
Externí odkaz:
https://doaj.org/article/e22f91bb33b34c45b99ef4b5ba01a266
Autor:
Yukio Hosomi, Takashi Seto, Makoto Nishio, Koichi Goto, Noboru Yamamoto, Isamu Okamoto, Kosei Tajima, Yusuke Kajihara, Nobuyuki Yamamoto
Publikováno v:
Thoracic Cancer, Vol 13, Iss 15, Pp 2192-2200 (2022)
Abstract Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor receptor mutation‐positive (EGFR+) non‐small cell lung
Externí odkaz:
https://doaj.org/article/bbe4a46ab03a49159a527e5397f1373b